Memantina Tad

Memantine, the active ingredient in Memantina Tad, is a NMDA receptor antagonist presented as an oral tablet for oral use. It works by reducing excitotoxic neuronal damage and is indicated for the management of moderate to severe Alzheimer’s disease in adult patients, aiming to preserve cognition and functional abilities.

GNH USA supplies Memantina Tad as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing for regulated markets. The company adheres to stringent quality standards and regulatory requirements.

Memantina Tad (memantine) acts on the glutamatergic pathway and is employed in the treatment of Alzheimer’s disease.

Alzheimer's disease (mild to moderate): improves cognition and daily functioning in patients. Alzheimer's disease (moderate to severe): helps preserve functional abilities as disease progresses. Alzheimer's disease (behavioral symptoms): may reduce agitation and aggression associated with the condition.

Memantina Tad may be associated with a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Dizziness: transient sensation of light‑headedness. - Headache: mild to moderate intensity. - Constipation: reduced bowel movements. - Confusion: occasional disorientation. - Hypertension: elevated blood pressure readings. - Fatigue: feeling of tiredness.

Serious or Rare Side Effects: - Stevens‑Johnson syndrome: severe skin reaction requiring immediate medical attention. - Seizures: convulsive episodes, especially in predisposed individuals. - Hepatic dysfunction: abnormal liver enzyme elevations. - Cardiac arrhythmia: irregular heart rhythm. - Psychosis: emergence of hallucinations or delusional thoughts.

When prescribing Memantina Tad, clinicians should consider the following precautions.

Renal impairment: assess kidney function and adjust dose if necessary. History of seizures: monitor closely for neurologic events. Cardiovascular disease: evaluate blood pressure and cardiac status. Concomitant NMDA antagonists: avoid combined use to prevent additive neurotoxicity. Pregnancy: safety unknown; avoid unless benefits outweigh risks. Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Memantina Tad can interact with other medicines; awareness of the interaction level guides clinical decisions.

Major Interactions (Avoid): - Amantadine: additive NMDA antagonism may increase neurotoxicity. - Ketamine: combined NMDA blockade can cause severe CNS depression. - Other NMDA antagonists: concurrent use should be avoided.

Moderate Interactions (Monitor Closely): - Diuretics: may potentiate hypotensive effects. - Antihypertensives: additive blood‑pressure lowering. - Anticholinergics: may worsen cognitive side effects. - CYP450 inhibitors: possible increase in memantine plasma levels. - CNS depressants: monitor for enhanced sedation.